PriceTargets.com logo

SI-BONE - SIBN Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $23.00
  • Forecasted Upside: 89.30%
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 6 Buy Ratings
  • 0 Strong Buy Ratings
$12.15 As of 11/20/2024 01:00 AM ET
▼ -0.17 (-1.38%)

This chart shows the closing price for SIBN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New SI-BONE Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SIBN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SIBN

Analyst Price Target is $23.00
▲ +89.30% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for SI-BONE in the last 3 months. The average price target is $23.00, with a high forecast of $32.00 and a low forecast of $18.00. The average price target represents a 89.30% upside from the last price of $12.15.

This chart shows the closing price for SIBN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 6 investment analysts is to buy stock in SI-BONE. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/30/2023
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/28/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/26/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/24/2024
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/24/2024
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/22/2024
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/21/2024
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/20/2024

Latest Recommendations

  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/20/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$19.00 ➝ $19.00
11/13/2024Truist FinancialBoost TargetBuy ➝ Buy$16.00 ➝ $18.00
11/13/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$19.00 ➝ $19.00
10/14/2024Truist FinancialLower TargetBuy ➝ Buy$18.00 ➝ $16.00
8/6/2024Morgan StanleyLower TargetOverweight ➝ Overweight$21.00 ➝ $19.00
8/6/2024Needham & Company LLCLower TargetBuy ➝ Buy$27.00 ➝ $19.00
8/6/2024Truist FinancialLower TargetBuy ➝ Buy$20.00 ➝ $18.00
7/15/2024Morgan StanleyLower TargetOverweight ➝ Overweight$25.00 ➝ $21.00
5/7/2024JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$32.00
5/7/2024Morgan StanleyLower TargetOverweight ➝ Overweight$26.00 ➝ $25.00
5/7/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$27.00
4/3/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$27.00
3/28/2024Piper SandlerInitiated CoverageOverweight$25.00
2/27/2024Morgan StanleyBoost TargetOverweight ➝ Overweight$25.00 ➝ $26.00
2/27/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$25.00
2/27/2024Truist FinancialReiterated RatingBuy ➝ Buy$26.00 ➝ $24.00
12/22/2023Truist FinancialBoost TargetBuy ➝ Buy$25.00 ➝ $26.00
12/4/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$25.00
11/7/2023Cantor FitzgeraldLower TargetOverweight ➝ Overweight$30.00 ➝ $25.00
11/7/2023Morgan StanleyLower TargetOverweight ➝ Overweight$30.00 ➝ $25.00
11/7/2023Needham & Company LLCLower TargetBuy ➝ Buy$32.00 ➝ $25.00
9/26/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$30.00
8/22/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$30.00
8/9/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$30.00
8/8/2023Truist FinancialLower TargetBuy ➝ Buy$33.00 ➝ $31.00
8/8/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$32.00
7/19/2023Truist FinancialBoost Target$28.00 ➝ $33.00
7/12/2023Needham & Company LLCBoost Target$27.00 ➝ $32.00
6/14/2023Bank of AmericaBoost Target$28.00 ➝ $33.00
5/2/2023Truist FinancialBoost Target$26.00 ➝ $28.00
5/2/2023Needham & Company LLCBoost Target$24.00 ➝ $27.00
2/28/2023Truist FinancialBoost TargetBuy$21.00 ➝ $26.00
2/28/2023Needham & Company LLCBoost TargetBuy$20.00 ➝ $24.00
2/28/2023Morgan StanleyBoost TargetOverweight$18.00 ➝ $22.00
2/28/2023Canaccord Genuity GroupBoost TargetBuy$21.00 ➝ $24.00
2/28/2023Cantor FitzgeraldBoost TargetOverweight$22.00 ➝ $24.00
1/31/2023Truist FinancialBoost TargetBuy$17.00 ➝ $21.00
1/6/2023Morgan StanleyLower TargetOverweight$21.00 ➝ $18.00
12/20/2022Truist FinancialLower TargetBuy$20.00 ➝ $17.00
11/16/2022Cantor FitzgeraldReiterated RatingOverweight
11/15/2022Morgan StanleyLower Target$21.00
11/8/2022Morgan StanleyLower TargetOverweight$22.00 ➝ $21.00
11/8/2022Needham & Company LLCLower TargetBuy$24.00 ➝ $22.00
11/8/2022JMP SecuritiesLower TargetMarket Outperform$36.00 ➝ $32.00
10/12/2022Jefferies Financial GroupInitiated CoverageBuy$20.00
10/11/2022Morgan StanleyBoost TargetOverweight$21.00 ➝ $22.00
8/9/2022Morgan StanleyBoost TargetOverweight$18.00 ➝ $21.00
8/9/2022Needham & Company LLCLower TargetBuy$28.00 ➝ $24.00
7/22/2022Truist FinancialLower Target$17.00
7/15/2022Morgan StanleyLower TargetOverweight$22.00 ➝ $18.00
6/1/2022JMP SecuritiesReiterated RatingBuy$36.00
5/10/2022Canaccord Genuity GroupLower Target$32.00 ➝ $25.00
4/7/2022Cantor FitzgeraldInitiated CoverageOverweight$34.00
3/1/2022Morgan StanleyLower TargetOverweight$30.00 ➝ $28.00
1/18/2022Bank of AmericaLower TargetBuy$43.00 ➝ $36.00
1/10/2022Needham & Company LLCReiterated RatingBuy$32.00
12/21/2021Truist FinancialLower TargetBuy$35.00 ➝ $30.00
12/13/2021Needham & Company LLCReiterated RatingBuy$32.00
11/9/2021Needham & Company LLCLower TargetBuy$37.00 ➝ $32.00
11/9/2021JMP SecuritiesLower TargetMarket Outperform$42.00 ➝ $36.00
9/30/2021Truist FinancialLower TargetBuy$43.00 ➝ $37.00
8/3/2021Morgan StanleyLower TargetOverweight$41.00 ➝ $40.00
8/3/2021Needham & Company LLCReiterated RatingBuy$42.00 ➝ $37.00
6/8/2021CitigroupInitiated CoverageBuy
5/4/2021Truist FinancialBoost Target$35.00 ➝ $43.00
5/4/2021Needham & Company LLCBoost TargetBuy$34.00 ➝ $42.00
5/4/2021Morgan StanleyBoost TargetOverweight$38.00 ➝ $41.00
4/19/2021Morgan StanleyBoost TargetOverweight$35.00 ➝ $38.00
3/9/2021Morgan StanleyBoost TargetOverweight$32.00 ➝ $35.00
3/9/2021Needham & Company LLCLower TargetBuy$35.00 ➝ $34.00
2/1/2021Needham & Company LLCReiterated RatingBuy$27.00
1/8/2021JMP SecuritiesBoost TargetOutperform$27.00 ➝ $35.00
12/16/2020Needham & Company LLCBoost TargetBuy$28.00 ➝ $35.00
12/15/2020Morgan StanleyBoost TargetOverweight$25.00 ➝ $32.00
9/30/2020JMP SecuritiesBoost TargetOutperform$22.00 ➝ $27.00
8/4/2020Morgan StanleyBoost TargetOverweight$20.00 ➝ $25.00
8/4/2020Needham & Company LLCBoost TargetBuy$22.00 ➝ $24.00
6/15/2020Cantor FitzgeraldInitiated CoverageBuy$25.00
6/8/2020Cantor FitzgeraldReiterated RatingOverweight
5/29/2020Needham & Company LLCReiterated RatingBuy$22.00
5/5/2020JMP SecuritiesLower TargetMarket Outperform$27.00 ➝ $22.00
5/5/2020Morgan StanleyBoost TargetOverweight$18.00 ➝ $20.00
5/5/2020Needham & Company LLCLower TargetBuy$27.00 ➝ $22.00
3/27/2020Morgan StanleyLower TargetOverweight$24.00 ➝ $18.00
2/19/2020Needham & Company LLCInitiated CoverageBuy$27.00
1/7/2020SunTrust BanksInitiated CoverageBuy$27.00
12/17/2019Cantor FitzgeraldInitiated CoverageOverweight$27.00
(Data available from 11/21/2019 forward)

News Sentiment Rating

0.56 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 7 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
4/25/2024
  • 10 very positive mentions
  • 13 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
5/25/2024
  • 3 very positive mentions
  • 1 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
6/24/2024
  • 7 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
7/24/2024
  • 13 very positive mentions
  • 9 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
8/23/2024
  • 9 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2024
  • 6 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2024
  • 6 very positive mentions
  • 19 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2024

Current Sentiment

  • 6 very positive mentions
  • 19 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

SI-BONE logo
SI-BONE, Inc., a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products. The company also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with the proprietary 3D-printed porous surface and fenestrated design; iFuse-TORQ, a set of 3D-printed threaded implants designed to treat pelvic trauma; and iFuse Bedrock Granite implant provides sacroiliac fusion and sacropelvic fixation as a foundational element for segmental spinal fusion. It markets its products primarily with a direct sales force, as well as through agents and resellers. SI-BONE, Inc. was incorporated in 2008 and is headquartered in Santa Clara, California.
Read More

Today's Range

Now: $12.15
Low: $12.07
High: $12.43

50 Day Range

MA: $13.85
Low: $12.15
High: $16.05

52 Week Range

Now: $12.15
Low: $11.76
High: $21.70

Volume

217,144 shs

Average Volume

392,037 shs

Market Capitalization

$509.57 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.22

Frequently Asked Questions

What sell-side analysts currently cover shares of SI-BONE?

The following sell-side analysts have issued stock ratings on SI-BONE in the last year: Cantor Fitzgerald, JMP Securities, Morgan Stanley, Needham & Company LLC, Piper Sandler, and Truist Financial Co..
View the latest analyst ratings for SIBN.

What is the current price target for SI-BONE?

0 Wall Street analysts have set twelve-month price targets for SI-BONE in the last year. Their average twelve-month price target is $23.00, suggesting a possible upside of 89.3%. JMP Securities has the highest price target set, predicting SIBN will reach $32.00 in the next twelve months. Truist Financial Co. has the lowest price target set, forecasting a price of $18.00 for SI-BONE in the next year.
View the latest price targets for SIBN.

What is the current consensus analyst rating for SI-BONE?

SI-BONE currently has 6 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe SIBN will outperform the market and that investors should add to their positions of SI-BONE.
View the latest ratings for SIBN.

What other companies compete with SI-BONE?

Other companies that are similar to SI-BONE include Surmodics, CryoLife, Orthofix Medical, Anika Therapeutics and Intersect ENT. Learn More about companies similar to SI-BONE.

How do I contact SI-BONE's investor relations team?

SI-BONE's physical mailing address is 471 EL CAMINO REAL SUITE 101, SANTA CLARA CA, 95050. The company's listed phone number is (408) 207-0700 and its investor relations email address is [email protected]. The official website for SI-BONE is www.si-bone.com. Learn More about contacing SI-BONE investor relations.